Altimmune (NASDAQ:ALT) Releases Quarterly Earnings Results

Altimmune (NASDAQ:ALT) announced its quarterly earnings data on Thursday. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.02), reports. The firm had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.00 million. Altimmune had a negative net margin of 419,575.00% and a negative return on equity of 54.79%.

Here are the key takeaways from Altimmune’s conference call:

• Strong Phase 2 results — pemvidutide showed early MASH resolution at 24 weeks and clear anti‑fibrotic activity with meaningful NIT, ALT and weight improvements at 48 weeks, supporting selection of 1.8 mg and evaluation of 2.4 mg for Phase 3.
• Regulatory progress — the FDA granted Breakthrough Therapy and End‑of‑Phase‑2 minutes confirmed alignment on a pivotal global Phase 3 (≈1,800 patients, biopsy and NIT cohorts) with dual primary endpoints designed to support Accelerated Approval.
• Phase 3 operational readiness — the company says overall design, dosing (1.2 mg start with one‑ or two‑step titration) and global site plans are defined, but final protocol details, biopsy reading approach and exact timelines remain being finalized.
• Near‑term catalysts — top‑line data from the AUD (RECLAIM) Phase 2 are expected in Q3 2026 and ALD Phase 2 enrollment should complete in 2026, offering potential label expansion but with outcome uncertainty.
• Financial and execution risk — Q4 net loss widened and OpEx will increase as Phase 3 approaches; management reports pro forma cash of roughly $340M (runway into 2028) but expects to access additional capital, implying potential dilution or financing risk.

Altimmune Stock Performance

Shares of ALT stock traded up $0.07 during trading on Friday, reaching $3.58. The company had a trading volume of 1,833,918 shares, compared to its average volume of 4,773,272. The firm’s 50 day simple moving average is $4.49 and its two-hundred day simple moving average is $4.28. Altimmune has a one year low of $2.90 and a one year high of $7.73. The company has a debt-to-equity ratio of 0.08, a current ratio of 17.18 and a quick ratio of 17.18. The company has a market capitalization of $403.93 million, a PE ratio of -3.35 and a beta of 0.13.

Insider Buying and Selling

In other Altimmune news, Director John Gill acquired 12,500 shares of Altimmune stock in a transaction dated Tuesday, December 23rd. The stock was bought at an average cost of $4.10 per share, with a total value of $51,250.00. Following the acquisition, the director owned 12,500 shares of the company’s stock, valued at approximately $51,250. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jerome Benedict Durso bought 12,500 shares of the stock in a transaction that occurred on Monday, December 22nd. The stock was acquired at an average cost of $4.13 per share, for a total transaction of $51,625.00. Following the purchase, the director owned 12,500 shares of the company’s stock, valued at $51,625. This trade represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 30,527 shares of company stock valued at $125,278 in the last ninety days. Company insiders own 4.40% of the company’s stock.

Institutional Trading of Altimmune

Several hedge funds have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Altimmune by 4.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company’s stock valued at $247,000 after acquiring an additional 2,241 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Altimmune by 10.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 27,945 shares of the company’s stock valued at $108,000 after acquiring an additional 2,748 shares during the last quarter. Deutsche Bank AG boosted its stake in Altimmune by 4.0% during the 4th quarter. Deutsche Bank AG now owns 79,940 shares of the company’s stock worth $289,000 after acquiring an additional 3,047 shares during the last quarter. Arax Advisory Partners increased its stake in Altimmune by 99.7% in the fourth quarter. Arax Advisory Partners now owns 8,165 shares of the company’s stock valued at $29,000 after purchasing an additional 4,076 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in Altimmune by 108.5% in the second quarter. BNP Paribas Financial Markets now owns 10,095 shares of the company’s stock worth $39,000 after purchasing an additional 5,253 shares during the period. Institutional investors and hedge funds own 78.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ALT. Barclays began coverage on shares of Altimmune in a research note on Tuesday, January 27th. They set an “overweight” rating and a $20.00 price objective on the stock. Citigroup restated a “market outperform” rating on shares of Altimmune in a research report on Wednesday, November 12th. William Blair reissued a “market perform” rating on shares of Altimmune in a report on Thursday. Citizens Jmp lowered their target price on Altimmune from $15.00 to $14.00 and set a “market outperform” rating on the stock in a research report on Friday, November 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Altimmune in a research report on Monday, December 29th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $17.60.

Altimmune News Summary

Here are the key news stories impacting Altimmune this week:

• Positive Sentiment: Company advancing pemvidutide clinical program — Altimmune plans to initiate a Phase 3 MASH (NASH with steatohepatitis) trial in 2026 and outlined an ~1,800‑patient Phase 3 design, which materially derisks the program if successful. This progress supports long‑term upside for the stock. Read More.
• Positive Sentiment: Regulatory boost — Pemvidutide received FDA Breakthrough Therapy Designation in MASH, which can accelerate development and increase the asset’s value. Read More.
• Positive Sentiment: Strong cash runway — Company reported $274M in cash, cash equivalents and short‑term investments as of 12/31/25 and completed a $75M registered direct offering in January, and management signaled runway into 2028. That reduces near‑term dilution/financing risk for clinical execution. Read More.
• Neutral Sentiment: Earnings call and analyst previews available — Transcripts and previews provide detail on timing (RECLAIM AUD topline expected Q3 2026) and trial design; useful for investors but not immediate price catalysts. Read More. • Read More.
• Neutral Sentiment: Short‑interest data appears anomalous — Recent reports show “0 shares” short interest and NaN changes, suggesting reporting errors; not a reliable signal for current trading pressure. (No external link)
• Negative Sentiment: Quarterly earnings miss — Altimmune reported Q4 EPS of ($0.27), missing the consensus of ($0.25). Revenue was immaterial ($0.03M) and the company shows deeply negative margins and ROE, underscoring it is still pre‑revenue/clinical‑stage and dependent on trial outcomes and funding. This miss is the primary near‑term negative driver for the share price. Read More.
• Negative Sentiment: Stock reacted down to the earnings miss — Market coverage noted the stock edging lower on the report, reflecting investor focus on short‑term financial metrics despite the pipeline positives. Read More.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.